News

DTMP-Prime Model Advances Prime Editing Predictions

Researchers in Iran and Germany have developed a deep-learning model, DTMP-Prime, to improve predictions for Prime Editing (PE) efficiency and pegRNA activity. Researchers can use the tool to select the best pegRNA and nick gRNA (ngRNA) combinations and to accurately predict the efficiency and outcomes of PE experiments.

By: Gorm Palmgren - Oct. 29, 2024
News

DTMP-Prime combines sophisticated feature selection, deep embedding, and multi-head attention layers to predict the efficiency of PE complexes by evaluating factors affecting pegRNA and target DNA sequence interactions. More than 43 features are used to enable the detailed analysis that reduces off-target effects and enhances editing outcomes, including pegRNA length, RNA folding structures, Cas9 activity, and nucleotide composition.

DTMP-Prime also uses DNABERT embeddings to capture nuanced relationships within DNA sequences, effectively identifying optimal pegRNA configurations for various PE systems, like PE2 and PE3. Performance comparisons with state-of-the-art PE prediction tools, such as DeepPE and Easy-Prime, demonstrate that DTMP-Prime achieves higher precision, with Pearson and Spearman correlation coefficients of 0.8 and 0.77, respectively, in test datasets.

This study was led by Leila Safari from the University of Zanjan, Iran, and Alireza Khanteymoori from the University of Freiburg. It was published today in Molecular Therapy: Nucleic Acids.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNewsHashtagPrime editors

News: DTMP-Prime Model Advances Prime Editing Predictions
CLINICAL TRIALS
Beta-Thalassemia, BT, (NCT06024876)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-dependent Beta-Thalassemia, TDT, (NCT06065189)
Sponsors:
Children's Hospital of Fudan University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-dependent Beta-Thalassemia, TDT, (NCT06291961)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine